ENZ:NYE-Enzo Biochem Inc. ($0.01 Par Value) (USD)

EQUITY | Diagnostics & Research | New York Stock Exchange

Last Closing

USD 0.728

Change

+0.02 (+2.78)%

Market Cap

USD 0.32B

Volume

0.17M

Analyst Target

USD 5.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Enzo Biochem Inc is engaged in research, development, manufacturing and marketing of health care products, platforms and services. The Company's business segments are Enzo Clinical Labs, Enzo Life Sciences, and Enzo Therapeutics.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-27 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
DHR Danaher Corporation

N/A

USD 165.08B
A Agilent Technologies Inc

N/A

USD 40.09B
IQV IQVIA Holdings Inc

N/A

USD 36.13B
LH Laboratory Corporation of Amer..

N/A

USD 19.12B
DGX Quest Diagnostics Incorporated

N/A

USD 17.09B
QGEN Qiagen NV

N/A

USD 10.26B
CRL Charles River Laboratories

N/A

USD 9.50B
VNRX Volitionrx Ltd

N/A

USD 0.06B
TMO Thermo Fisher Scientific Inc

N/A

N/A
MTD Mettler-Toledo International I..

N/A

N/A

ETFs Containing ENZ

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -47.63% 8% B- 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -47.63% 8% B- 4% F
Trailing 12 Months  
Capital Gain -47.63% 8% B- 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -47.63% 8% B- 4% F
Trailing 5 Years  
Capital Gain -72.53% 17% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -72.53% 17% F 4% F
Average Annual (5 Year Horizon)  
Capital Gain -10.56% 15% F 5% F
Dividend Return -10.56% 15% F 5% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 35.48% 23% F 29% F
Risk Adjusted Return -29.76% 15% F 8% B-
Market Capitalization 0.32B 11% F 17% F

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 7.10 13% 1%
Price/Book Ratio 0.84 100% 81%
Price / Cash Flow Ratio -1.52 89% 85%
Price/Free Cash Flow Ratio -3.27 100% 89%
Management Effectiveness  
Return on Equity -14.59% 22% 18%
Return on Invested Capital -37.88% 11% 6%
Return on Assets -7.44% 22% 11%
Debt to Equity Ratio 0.34% 88% 93%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector